1. Sun, Wei, Jin, Yongjia, Wei, Chuanyuan, Xiang, Yang, Chen, Yong. 2023. CDCA2 promotes melanoma progression by inhibiting ubiquitin-mediated degradation of Aurora kinase A. In European journal of cancer (Oxford, England : 1990), 188, 49-63. doi:10.1016/j.ejca.2023.04.005. https://pubmed.ncbi.nlm.nih.gov/37196484/
2. Gao, Jun, Wang, Huaqiao, Qiu, Xiujuan, Tang, Jianjun. 2023. E2F3/CDCA2 reduces radiosensitivity in gastric adenocarcinoma by activating PI3K/AKT pathway. In The British journal of radiology, 96, 20230477. doi:10.1259/bjr.20230477. https://pubmed.ncbi.nlm.nih.gov/37750838/
3. Li, Kai, Fan, Tingting, Shi, Zhongxing, Jiang, Huijie. 2022. CDCA2 Promotes HCC Cells Development via AKT-mTOR Pathway. In Analytical cellular pathology (Amsterdam), 2022, 9912254. doi:10.1155/2022/9912254. https://pubmed.ncbi.nlm.nih.gov/36588796/
4. Jin, W-H, Zhou, A-T, Chen, J-J, Cen, Y. . CDCA2 promotes proliferation and migration of melanoma by upregulating CCAD1. In European review for medical and pharmacological sciences, 24, 6858-6863. doi:10.26355/eurrev_202006_21675. https://pubmed.ncbi.nlm.nih.gov/32633378/
5. Wang, Shouping, Cao, Kun, Liao, Yuting, Chen, De, Wang, Yanjie. 2021. CDCA2 protects against oxidative stress by promoting BRCA1-NRF2 signaling in hepatocellular carcinoma. In Oncogene, 40, 4368-4383. doi:10.1038/s41388-021-01855-w. https://pubmed.ncbi.nlm.nih.gov/34103686/
6. Jin, Xin, Sun, Zhen-Qing, Zhou, Gui-Liang, Li, Guo-Jun, Deng, Shi-Feng. 2022. The Higher Expression of CDCA2 Associated with Poor Prognosis in Glioma. In Disease markers, 2022, 2184867. doi:10.1155/2022/2184867. https://pubmed.ncbi.nlm.nih.gov/35386230/
7. Tang, Mengying, Liao, Mingchu, Ai, Xiaohong, He, Guicheng. 2022. Increased CDCA2 Level Was Related to Poor Prognosis in Hepatocellular Carcinoma and Associated With Up-Regulation of Immune Checkpoints. In Frontiers in medicine, 8, 773724. doi:10.3389/fmed.2021.773724. https://pubmed.ncbi.nlm.nih.gov/35372372/
智鼠故事 
